Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FOUND: Masimo corp - What They Never Told You

Apple Restores Blood-Oxygen Tracking To Watch After Customs Ruling — Masimo Strikes Back With Lawsuit Over Patent Rights

Apple Inc. (NASDAQ:AAPL) has reintroduced the blood-oxygen monitoring feature to its Apple Watch lineup after U.S. Customs and Border Protection approved imports of the devices — a decision that medical technology firm Masimo Corp. (NASDAQ:MASI) is now challenging in court.

Benzinga · Aug 21, 2025

Apple could still rescue the Watch 9 and Ultra 2 from a ban with rare software fix

Apple is desperately working on software patches in a bid to avert a ban on the Apple Watch.

TechRadar · Dec 19, 2023

Apple Pauses US Sale Of Latest Watch Models Over Patent Clash

Apple on Monday said it will stop selling some of its smartwatch models in the United States while it fights a patent battle over technology for detecting blood oxygen levels.

International Business Times · Dec 18, 2023

From analysis to the latest developments in health,
read the most diverse news in one place.

Masimo Posts Better Than Expected Q1 Earnings Despite 'Unexpected' Supply Chain Issues

Masimo Corp's (NASDAQ:MASI) Q1 revenue increased 1.7% Y/Y (+3.2% on a constant currency basis) to $304.2 million, beating the consensus of $303.83 million. Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 75,700 in Q1 of 2022. The adjusted operating margin remained unchanged at 22.9%. The company reported…

Benzinga · May 4, 2022

Supply Chain Challenges To Hit Masimo's Q1 FY22 Sales

Masimo Corp (NASDAQ:MASI) expects Q1 FY22 product revenue of $285 million - $315 million, lower than expected. Shortages of critical components and other supply chain issues, including freight carrier delays, have led to lower-than-expected sales in the first quarter. Related: Joe Kiani, Chairman, and CEO, said, "In prior quarters, we were able…

Benzinga · Mar 31, 2022

Needham Upgrades Masimo To Buy, With Price Target Of $205

Needham has upgraded Masimo Corp (NASDAQ: MASI) to Buy from Hold with a $205 price target

Benzinga · Feb 18, 2022

Masimo Stock Plunges After Q4 Results, Sound United Deal

Masimo Corp's (NASDAQ: MASI)

Benzinga · Feb 16, 2022

Read news from The Economist, FT, and more,
with one subscription

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.